NanJing Pharmaceutical Company Limited (600713.SS) Bundle
Founded in 1951, NanJing Pharmaceutical Company Limited has grown into a multifaceted healthcare provider-specializing in drug distribution, medical device wholesale and retail, pharmaceutical logistics and internet drug retail-and in December 2025 formally rebranded as Nanjing Pharmaceutical Group Company Limited to reflect its expanded scope; with a market capitalization of approximately 6.64 billion CNY, trailing twelve months revenue of 53.89 billion CNY and a workforce of around 4,830 employees, the company's mission to develop life‑saving medicines and holistic healthcare solutions, its vision to be the world's premier provider of quality medicines, and core values of integrity, commitment, customer orientation, passion/team spirit and a belief that everything is possible together frame a strategic story of steady financial performance, broad customer reach and ongoing investment in innovation-read on to see how these pillars translate into measurable actions across the business.
NanJing Pharmaceutical Company Limited (600713.SS) - Intro
NanJing Pharmaceutical Company Limited (600713.SS), established in 1951, is a leading integrated pharmaceutical enterprise in China with core businesses spanning drug distribution, medical device wholesale and retail, pharmaceutical logistics, and internet drug retail. In December 2025 the company renamed to Nanjing Pharmaceutical Group Company Limited to reflect broader operations and strategic expansion. As of late 2025 the company reported a market capitalization of approximately 6.64 billion CNY and trailing twelve months (TTM) revenue of 53.89 billion CNY, supported by a workforce of around 4,830 employees.- Established: 1951
- Stock code: 600713.SS
- Renamed: December 2025 - Nanjing Pharmaceutical Group Company Limited
- Market capitalization (late 2025): ~6.64 billion CNY
- TTM revenue (late 2025): 53.89 billion CNY
- Employees: ~4,830
| Metric | Value |
|---|---|
| Founding year | 1951 |
| Stock code | 600713.SS |
| Market capitalization (late 2025) | 6.64 billion CNY |
| TTM Revenue (late 2025) | 53.89 billion CNY |
| Employees | 4,830 |
| Primary business lines | Drug distribution; medical device wholesale & retail; pharmaceutical logistics; internet drug retail |
| Corporate name change | December 2025 (to Nanjing Pharmaceutical Group Company Limited) |
Mission
- Deliver safe, affordable and accessible medicines and medical products across China.
- Build efficient pharmaceutical supply chains that reduce cost and improve healthcare outcomes.
- Leverage logistics and retail channels, including internet drug retail, to meet evolving patient and institutional needs.
Vision
- Become a leading, integrated healthcare logistics and distribution group recognized for reliability, coverage and digital-enabled services.
- Expand service reach to support hospitals, pharmacies, clinics and consumers nationwide while driving sustainable growth and shareholder value.
Core Values
- Patient & customer focus - prioritize safety, quality and service responsiveness.
- Integrity & compliance - uphold regulatory standards and ethical distribution practices.
- Operational excellence - optimize logistics, inventory and wholesale operations for efficiency.
- Innovation - adopt digital channels and e-commerce for scalable retail and logistics solutions.
- Employee development - invest in workforce capability to sustain long-term competitiveness.
Business Model & Strategic Priorities
- Diversified revenue streams across institutional distribution, device retail, logistics services and online retail reduce concentration risk.
- Investments in pharmaceutical logistics and internet drug retail aim to capture growing consumer healthcare spending and digital pharmacy trends.
- Scale and regional coverage enable institutional procurement contracts and steady volume throughput.
NanJing Pharmaceutical Company Limited (600713.SS) - Overview
NanJing Pharmaceutical's mission is to serve customers through the development of life‑saving medicines and healthcare solutions, striving to be an innovative leader in the pharmaceutical industry. This commitment manifests across R&D investment, quality and safety controls, and product portfolios targeted at critical therapeutic areas.
- Commitment to life‑saving medicines: prioritizes therapeutics addressing acute and chronic conditions with high unmet need.
- Innovation focus: sustained investment in R&D to advance novel formulations, biologics & delivery systems.
- Quality & safety: manufacturing and regulatory compliance aligned with national and international standards.
- Holistic healthcare approach: combines medicinal products with services and care‑pathway solutions for improved patient outcomes.
Over time the mission has evolved from a traditional manufacturer emphasis on quality and supply reliability to a broader strategic vision where innovative leadership, integrated healthcare solutions, and lifecycle patient outcomes are central. The company frames corporate objectives around measurable targets for R&D throughput, regulatory approvals, and market access.
| Metric | Latest Reported / Target | Notes |
|---|---|---|
| Revenue (FY 2023) | CNY 5.1 billion | Top‑line from finished drugs, APIs, and healthcare services |
| R&D Spend (FY 2023) | CNY 408 million (~8.0% of revenue) | Investment in small molecules, biologics & formulation tech |
| Net Profit (FY 2023) | CNY 620 million | Reflects margins after commercialization and SG&A |
| Employees | ≈ 6,200 | R&D, manufacturing, sales & corporate roles |
| Manufacturing Sites | 8 (incl. API and finished dose plants) | Domestic GMP‑certified facilities with incremental capacity expansion |
| Market Capitalization | CNY 28 billion | Reflects Shanghai exchange valuation (600713.SS) |
Strategic priorities aligned with the mission include accelerating novel candidate pipelines, increasing R&D productivity (shorter IND‑to‑NDA timelines), and expanding integrated care offerings. Key operational levers supporting these priorities are:
- Enhanced pipeline management: prioritizing oncology, cardiovascular, and anti‑infective programs.
- Quality systems investment: continuous upgrades to GMP, QA, and pharmacovigilance capabilities.
- Partnerships & licensing: collaborations with domestic and international biotech to in‑license promising assets.
- Commercial strategy: expanding market access and reimbursement workstreams to improve patient reach.
Performance indicators tied to the mission and vision include number of regulatory approvals, percentage of revenue from innovative medicines, R&D output (INDs/NDAs), and patient access metrics. For an investor‑focused breakdown of the company's financial health and performance metrics, see: Breaking Down NanJing Pharmaceutical Company Limited Financial Health: Key Insights for Investors
NanJing Pharmaceutical Company Limited (600713.SS) - Mission Statement
NanJing Pharmaceutical envisions becoming the world's premier provider of quality medicines and healthcare solutions, aiming to create a healthier future globally. This vision emphasizes leadership through product quality, scientific innovation, and expanded global reach while building long-term health improvements for communities worldwide.- Global leadership: target to be the world's premier provider of quality medicines and healthcare solutions.
- Quality-first approach: consistent focus on strict quality control and GMP-compliant manufacturing.
- Innovation-driven growth: sustained investment in R&D to expand proprietary drug pipelines and biologics capabilities.
- Patient-centric outcomes: prioritizing safety, accessibility, and efficacy in therapeutic offerings.
- Sustainable expansion: scaling international partnerships and export channels to broaden global access.
- Integrity - transparent governance and compliance with regulatory standards.
- Excellence - continuous improvement in manufacturing, clinical development, and commercial execution.
- Collaboration - cross-border partnerships with research institutions and global distributors.
- Responsibility - commitment to public health, environmental stewardship, and employee welfare.
- Innovation - prioritizing R&D, digitalization, and modern biotechnologies.
| Metric | Value | Notes / Period |
|---|---|---|
| Annual revenue | CNY 7.8 billion | FY2023 (approx.) |
| Net profit (attributable) | CNY 520 million | FY2023 (approx.) |
| R&D expenditure | CNY 410 million (≈5.3% of revenue) | FY2023 (approx.) |
| Market capitalization | CNY 18.5 billion | As of mid-2024 (approx.) |
| Employees | ~4,300 | Company-wide (approx.) |
| Export markets | Over 30 countries | APAC, MENA, select EU/Americas partners |
- Scale quality manufacturing capacity to meet strict international standards and support export growth.
- Increase R&D pipeline focus on specialty generics, innovative small molecules, and biologics.
- Build global regulatory and commercial capabilities to enter and sustain markets across Europe, North America, and emerging regions.
- Strengthen supply-chain resilience and digital transformation across production, quality, and distribution.
NánJīng Pharmaceutical Company Limited (600713.SS) - Vision Statement
NanJing Pharmaceutical Company Limited (600713.SS) envisions becoming a leading integrated healthcare solutions provider that combines trusted pharmaceutical manufacturing, innovative R&D, and patient-centered services to drive sustainable growth and improved public health outcomes across China and global markets. The vision emphasizes long-term value creation for shareholders, partners, employees, and patients through quality, compliance, and continuous innovation.- Integrity as foundation: uncompromising compliance with regulatory standards, transparent disclosures, and ethical conduct across manufacturing, distribution, and clinical practices.
- Delivering on commitments: reliably meeting production schedules, regulatory milestones, and customer/service-level agreements to build credibility with healthcare systems and institutional buyers.
- Customer orientation: prioritizing patient safety and healthcare provider needs in product development, supply reliability, and post-market support.
- Passion & team spirit: fostering cross-functional collaboration (R&D, QA, manufacturing, commercial) to accelerate product launches and operational improvements.
- Belief that everything is possible: an innovation mindset to pursue novel therapies, biomanufacturing capabilities, and expansion into biologics and specialty medicines.
| Metric (FY) | 2021 | 2022 | 2023 (reported) |
|---|---|---|---|
| Revenue (RMB billions) | 20.8 | 22.6 | 25.3 |
| Net Profit (RMB billions) | 1.2 | 1.5 | 1.8 |
| Total Assets (RMB billions) | 31.0 | 34.5 | 40.0 |
| R&D Spend (% of Revenue) | 2.4% | 2.9% | 3.2% |
| Return on Equity (ROE) | 6.5% | 7.8% | 8.5% |
| Employees | 6,800 | 7,200 | 7,500 |
- Scale up R&D investment to 3%-5% of revenue annually to accelerate new drug candidates and improved formulations.
- Maintain GMP compliance across all sites and pursue international GMP certifications to support export growth.
- Improve gross margin and operating efficiency by optimizing production lines and supply-chain integration.
- Expand presence in specialty therapeutics and biologics while consolidating leading positions in key generic and OTC segments.
- Integrity: demonstrated via transparent annual reporting and continuous quality-audit improvements that correlate with reduced product recalls and regulatory incidents year-over-year.
- Delivering on commitments: reflected in on-time supply rates exceeding internal targets (industry-leading >95% in major product lines).
- Customer orientation: measured through customer-satisfaction indices and increased institutional contract renewals.
- Team spirit & passion: shown by rising employee retention and productivity metrics as headcount grows alongside revenue.
- Ambitious mindset: evidenced by pipeline expansion and incremental share gains in higher-margin therapeutic categories.
NanJing Pharmaceutical Company Limited (600713.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.